Sign Out
Primary hypercholesterolaemia or mixed dyslipidaemia (type IIb) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise, weight reduction) is inadequate.
Homozygous familial hypercholesterolaemia as an adjunct to diet and other lipid lowering treatments (e.g. LDL apheresis) or if such treatments are not appropriate.
Prevention of cardiovascular events: Prevention of major cardiovascular events in patients who are estimated to have a high risk for a first cardiovascular event (see PHARMACOLOGY: Pharmacodynamics under Actions), as an adjunct to correction of other risk factors.
Slow or delay the progression of atherosclerosis.
Children and adolescents 6 to 17 years of age: Rosuvastatin Sandoz is indicated to reduce the Total cholesterol, LDL-C and Apo B in patients with heterozygous familial hypercholesterolaemia (HeFH).
